JAK2 and myeloproliferative disorder: This domain has been shown to be necessary for receptor interaction and JAK2 activation, as the oncogenic JAK2 V617F mutation within the pseudokinase domain, found in myeloproliferative neoplasms, requires an intact SH2 domain [47, 59].